Six Years of High-Level Levodopa Therapy in Severely Akinetic Parkinsonian Patients

doi:10.1001/archneur.1976.00500050019004

You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.

Vol. 33 No. 5, May 1976

Online Only
	•	Online First Table of Contents

ARTICLES

•	Online Features

This Article
•	References
•	Full text PDF
•	Reply to article
•	Send to a friend
•	Save in My Folder
•	Save to citation manager
•	Permissions

Citing Articles
•	Citation map
•	Citing articles on HighWire
•	Citing articles on Web of Science (114)
•	Contact me when this article is cited

Related Content
•	Similar articles in this journal

Social Bookmarking
	What's this?

Six Years of High-Level Levodopa Therapy in Severely Akinetic Parkinsonian Patients

André Barbeau, MD, FRCP(C)

Arch Neurol. 1976;33(5):333-338.

Abstract

• The clinical course and the side effects of high-levellevodopa therapy over a six-year period were studied in 80 severelyakinetic parkinsonian patients treated for the first time beforeJune 1968. Levodopa improved the quality of life in greaterthan 53% of patients, but failed to modify the progression ofthe disease or change the prognosis. Seventeen "idiopathic Parkinson"patients died after a duration of illness of 9.5 years. Despitethe drawbacks, levodopa is still the best available treatmentfor akinetic parkinsonism.

Author Affiliations

From the Department of Neurobiology, Clinical Research Institute of Montreal, the Department of Medicine, University of Montreal, and the Hôtel-Dieu Hospital, Montreal.

Footnotes

Accepted for publication March 25, 1975.

Reprint requests to Clinical Research Institute of Montreal,110 Pine Ave W, Montreal, Quebec, Canada H2W 1R7 (Dr Barbeau).

Add to CiteULike CiteULike Add to Connotea Connotea Add to Delicious Delicious Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Estimated life expectancy of Parkinson's patients compared with the UK population
Ishihara et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:1304-1309.
ABSTRACT | FULL TEXT

Survival in Parkinson disease: Thirteen-year follow-up of the DATATOP cohort
Marras et al.
Neurology 2005;64:87-93.
ABSTRACT | FULL TEXT

Freezing of gait in PD: Prospective assessment in the DATATOP cohort
Giladi et al.
Neurology 2001;56:1712-1721.
ABSTRACT | FULL TEXT

Mortality from Parkinson's disease
CLARKE
J. Neurol. Neurosurg. Psychiatry 2000;68:254-255.
FULL TEXT

The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years
Hely et al.
J. Neurol. Neurosurg. Psychiatry 1999;67:300-307.
ABSTRACT | FULL TEXT

From off-period dystonia to peak-dose chorea: The clinical spectrum of varying subthalamic nucleus activity
Krack et al.
Brain 1999;122:1133-1146.
ABSTRACT | FULL TEXT

CNS Dopamine Receptors: Effect of Prolyl-Leucyl-Glycinamide and Solubilization
Mishra
Nutrition and Health 1984;3:175-187.
ABSTRACT

Epidemiology of Parkinson's Disease in a Japanese City
Harada et al.
Arch Neurol 1983;40:151-154.
ABSTRACT

| | |